Stopping Smoking Reduces Mortality in Low-Dose Computed Tomography (LDCT) Screening Volunteers

WCLC 2015

Contact: Jeff Wolf                                                                                                  Chris Martin                                       
IASLC Director of Communications                                                                   Public Relations Manager         | 720-325-2952                                                    | 630-670-2745                                                                                                  

Becky Bunn
IASLC Projects Specialist | 720-325-2946


Stopping Smoking Reduces Mortality in Low-Dose Computed Tomography (LDCT) Screening Volunteers

DENVER, Colo. — Smoking cessation among patients enrolled in a low-dose computed tomography screening program is associated with a three-to-five times reduction in mortality, according to research presented today at 16th World Conference on Lung Cancer (WCLC) hosted by the International Association of the Study of Lung Cancer (IASLC) in Denver.

Dr. Ugo Pastorino, Director Thoracic Surgery, IRCCS Istituto Nazionale dei Tumori Foundation, Milan, Italy, analyzed 3,318 heavy smokers enrolled in LDCT screening efforts. Subjects were divided into two groups: current smokers and former smokers, the latter including ex-smokers at the time of baseline screening and those who stopped smoking during the screening period.

Dr. Pastorino developed this study because, while screening programs like The National Lung Screening Trial (NLST) have achieved a 7 percent reduction in mortality from any cause with low-dose computed tomography (LDCT) screening, no study previously examined the impact of smoking habits on screening outcome.

After following up with enrolled patients, Pastorino’s team noted 151 deaths among the smoking group and 109 deaths among those who had stopped smoking. Compared with the group of current smokers, those who stopped smoking had a 23 percent reduction in mortality.

“Stopping smoking is associated with a significant reduction of the overall mortality of heavy smokers enrolled in LDCT screening programs,” he reported. “The benefit of stopping smoking appears to be 3 to 5-fold greater than the one achieved by earlier detection in the NLST trial.”


About the WCLC:

The WCLC is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, attracting more than 7,000 researchers, physicians and specialists from more than 100 countries. The conference goal is to increase awareness and collaboration so that the latest developments in lung cancer can be understood and implemented throughout the world. Falling under the theme of “Fighting Lung Cancer,” the conference will cover a wide range of disciplines and unveil several research studies and clinical trial results. For the first time, IASLC has invited survivors to attend the conference free of charge. For more information on the 2015 WCLC, visit:

About the IASLC:

The International Association for the Study of Lung Cancer (IASLC) is the only global organization specifically dedicated to the study of lung cancer. Founded in 1974, the association's membership includes nearly 4,000 lung cancer specialists in 80 countries. For more information, visit:


September 9, 2015